lemme glp-1 daily Daily™ Lemme GLP-1 Daily Review: What

Clinical Significance: The 2025 updates reaffirm that while HbA1c remains central, a one-number-fits-all strategy is outdated

Recapping the headlines that affected American's health in 2025

Among the marketed large molecule injectable GLP-1 agonists, semaglutide, apart from weight-loss, is being studied for kidney disease and tirzepatide (a dual GLP-1 and GIP receptor agonist) is being evaluated for sleep apnea in Ph 3 clinical trials

The GLP-1 drugs market size is predicted to grow from USD 58.05 billion in 2026 to USD 132.79 billion by 2035, driven by a CAGR of 9.63%.

Compare Mounjaro vs Ozempic to understand their differences, benefits, and effectiveness in medical weight management.

Here's how to address root causes of metabolic health and infertility for long term success.